In 2019, he received the Venia legendi for experimental pharmacology from the Medical Faculty at the University of Tübingen, Germany. Timo Müllers research is focused on the development and evaluation of novel unimolecular pharmacotherapies to treat the metabolic syndrome, and in particular obesity and diabetes. He is part of an international team of scientists who pioneered the concept of GLP-1-based dual-and triple-agonists for the treatment of obesity and diabetes.

Timo Müller refuted the concept that alternatively activated macrophages regulate adaptive thermogenesis (Fischer et al., Nat Med 2017), identified the signal mechanism of how p62 regulates energy metabolism (Fischer et al., Nat Commun 2020) and identified the CNS GIP receptor as a key regulator of body weight (Zhang et al., Cell Metab 2021). He also published two of the most cited manuscripts of Molecular Metabolism (Müller et al., Mol Metab 2015 and Müller et al., Mol Metab 2019).